are two main theories as to why this placental graft is deficient. One theory is that there is an immunological disturbance, and the other is that there is a vascular insufficiency of the placenta. 4 Acute therapy for eclampsia is vital for survival, and therapy for the severe pre-eclamptic state is almost as dire an emergency. Ofrecent times there has been controversy concerning the use of sodium nitroprusside (SNP) to lower the seriously raised blood pressure with some successful reports,5,6 some reports indicating poor foetal outcome 7 and some equivocal reports. 8 I wish to report further successful administrations of SNP in the management of this syndrome of severe gestosis.
Clinical management of the patient with severe gestosis
The first consideration must be the control of any fitting and associated hypoxia. This is often by means of intravenous diazepam initially. This usually successfully controls the fitting, but if it does not then thiopentone is most useful. Such acute management may require endotracheal intubation and ventilation to ensure adequate 15, 16 In intensive care SNP is the best acute hypotensive agent for serious hypertension,12,17 and when accompanied by plasma infusion to overcome the severe hypovolaemia it should be the ideal therapy to be employed in the acute phase. Blood volume expansion will require considerable fluid volume if the hypertension is severe. Joyce and colleagues 18 showed that the more severe the diastolic blood pressure the lower the central venous pressure (CVP) and the more fluid volume that was required to restore normovolaemia; Gallery and her colleagues 19 have shown that plasma volume is lower with more severe hypertension, and have also shown that plasma volume expansion had an antihypertensive effect by itself. 20 My practice is to place a CVP cath'eter to mon~tor for an acute pressure rise with rapid infusion of stable plasma protein solution (SPPS). I have not found it necessary to place a pulmonary artery catheter in this condition, though it may be necessary ifthere is any suggestion of myocardial complication. Pulmonary oedema may appear in the face of low wedge pressure measurement and pulmonary artery monitoring is, in general, no more reliable than a CVP in this condition (the exception being with intrinsic myocardial disease). This opinion is also held by Goodlin. 2 The volume expander which I use is SPPS because there is a plasma volume deficit. Initially a litre is infused very rapidly and the patient reassessed. A second litre is then infused over an hour with possibly a third in the next hour depending on response to the CVP measurement, urine volume and blood gases or chest X-ray.
The aim is to control the severity of the hypertension and not to lower it to 'normal' levels. Therefore the diastolic blood pressure is lowered to 100-120 mmHg and the systolic to 140-160 mmHg initially, unless the presenting blood pressure was of this order when lower readings may be sought. I believe this is particularly important until good plasma volume expansion has occurred. The use of droperidol to control sympathetic surges with agitation is particularly useful at this time.
This acute control of the blood pressure and blood volume must be accompanied by suitable long-term anticonvulsive therapy such as phenytoin: by sedation and sympatholytic therapy such as provided by droperidol; and by osmotic diuretic such as mannitol to encourage diuresis to prevent kidney damage rather than to try to cure the oedema.
Subsequent therapy may be· required to treat other major organ complication. Such therapy will need to be specific and will not be dealt with further in this article.
Following stabilisation of the acute problem, further management then depends upon management of the pregnancy. If the patient is post partum there is need only to manage the mother. This management relies on weaning from SNP onto other hypotensive agents such as prazosin, nifedipine and labetalol with all these drugs often used in the stabilisation phase.
If there is a live foetus still in utero then management depends on the viability of the foetus. If it is possible to proceed to caesarian section then this is preferable as soon as the mother is stable and the baby is prepared. This may be possible in four to six hours from the initial emergency or may be delayed for foetal reasons for 24-36 hours. Tables 3-6 . The variation in therapy received by patients is due to the variation in obstetric and medical therapy prior to admission to the I CV, and thereafter to the individual patient variation in response to therapy.
All mothers made an uneventful recovery with the exception of patient 5 whose hypertensive state recurred 36 hours after discharge from the intensive care unit. In retrospect this patient was prematurely discharged from the ICD. All patients with the exception of patient 6 returned to a normal blood pressure without therapy at the three month follow-up appointment. Patient 6 was a known hypertensive and her resting blood pressure remained high, requiring continuing therapy. There was no complication of any of the medical therapy.
As can be seen the neonatal weights and ages were mostly reasonable with the exception of the intra-uterine death which had been diagnosed prior to the emergency situation developing. SNP was administered for a maximum of six hours prior to delivery but was continued in many mothers for up to 36-48 hours for adequate control of blood pressure. 
In all neonates there were no problems. At least for six hours and with adequate plasma expansion, SNP was safe for these mothers and their babies. The concern with SNP has been that there is a risk of cyanide toxicity due to breakdown of SNP with transmission across the placenta. There is some experimental work 21 to support this contention but the work was performed in pregnant ewes who were normotensive and whose blood pressure was lowered to an abnormally low level. This mimics the early work on induced hypotension with SNP in neurosurgery which led in certain patients to death with acidemia. 22 ,23 These early reports in the anaesthetic literature are now of historical interest because of better blood volume control and the use of adjuvant therapy to lower the blood pressure as well as SNP: there are no further cases appearing. I believe that the experimental foetal deaths in the study by Naulty and colleagues 21 may have been due to acidemia and placental ischaemia. There are other reports of successful usage of SNP in treatment of severe hypertension in pregnant ewes 24 and in humans. 6 The present series of patients now adds to this success with short-term use of SNP. The long-term use of SNP in situations where there is a need to delay delivery until the foetus is viable as yet remains unclear. In such situations it would be wise to replace SNP as soon as possible or to administer cyancobalamin to protect the foetus as much as possible from the effects of cyanide. Cotton and colleagues 25 report the use of intravenous glyceryl trinitrate to lower the blood pressure, and this drug may be useful to substitute for SNP after the initial few hours of acute therapy for the malignant hypertension. Nevertheless SNP is the choice of therapy to control the acute hypertensive crisis at any stage of pregnancy because of its superior hypotensive qualities.
